School of Medicine, Loma Linda University, USA.
J Neurointerv Surg. 2010 Dec;2(4):394-8. doi: 10.1136/jnis.2009.001453. Epub 2010 May 6.
Spinal cord intramedullary arteriovenous malformations (AVMs) pose a therapeutic challenge. Because of their complex angioanatomy, surgical excision of these lesions is difficult at best. Over the past decade, endovascular therapy has been established as an alternative treatment modality. As an embolic agent, N-butyl cyanoacrylate (NBCA) posed several problems such as difficulty of use and unpredictable performance. Onyx (ev3, Irvine, California, USA), an alternative liquid embolic agent, possesses several advantageous properties, such as increased control of agent delivery, over previous embolic agents like NBCA. However, reports of Onyx use in treating spinal intramedullary AVMs are still rare, especially in paediatric patients. We report a paediatric patient with glomus-type spinal intramedullary AVM treated successfully with Onyx with intermediate-term outcome.
脊髓髓内动静脉畸形(AVM)治疗具有挑战性。由于其复杂的血管解剖结构,手术切除这些病变充其量是困难的。在过去的十年中,血管内治疗已被确立为一种替代治疗方法。作为一种栓塞剂,N-丁基氰基丙烯酸酯(NBCA)存在使用困难和不可预测性能等问题。Onyx(ev3,加利福尼亚州欧文市,美国),一种替代的液态栓塞剂,具有增加的控制药物输送等优势,优于以前的栓塞剂,如 NBCA。然而,关于使用 Onyx 治疗脊髓髓内 AVM 的报道仍然很少,特别是在儿科患者中。我们报告了一例成功使用 Onyx 治疗的儿童型脊髓髓内 AVM 患者,其中期结果良好。